Olufunmilayo I. Olopade, MD, FACP, is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk-reducing strategies and prevention in high-risk populations, as well as earlier detection through advanced imaging technologies. She is a Co-Chair of the SickleInAfrica Consortium of Sickle Cell Disease Research in 7 countries of Sub-Saharan Africa.

Dr. Olopade is internationally renowned for her expertise in breast cancer, and her research has advanced early detection, treatment and prevention of breast cancer in women at high risk for the disease. A distinguished scholar and mentor, Olopade has received numerous honors and awards including honorary degrees from six universities and a 2005 MacArthur Fellowship (“Genius grant”) for “translating findings on the molecular genetics of breast cancer in African and African-American women into innovative clinical practices in the United States and abroad.”

Dr. Olopade has received numerous honors and awards, including honorary degrees from North Central, Dominican, Bowdoin, and Princeton universities. She is also a recipient of the Doris Duke Distinguished Clinical Scientist and Exceptional Mentor Award, an American Cancer Society Clinical Research Professorship, a MacArthur Foundation "Genius" Fellowship, and Officer of the Order of the Niger Award. Dr. Olopade is an elected member of the American Academy of Arts and Sciences, the American Philosophical Society, and the National Academy of Sciences. She currently serves on the board of directors for the American Board of Internal Medicine, the National Cancer Advisory Board, Susan G. Komen for the Cure, Cancer IQ, and the Lyric Opera.